The Role of C-Reactive Protein in Predicting Atherosclerotic Cardiovascular Disease Risk: A Review of the Evidence from 2000-2010

Abstract

Introduction: The first decade of the 21st century heralded a paradigm shift in cardiology, moving from a purely lipid-centric model of atherosclerosis to one that embraced the disease as a chronic inflammatory process. Within this new framework, high-sensitivity C-reactive protein (hs-CRP), a downstream marker of systemic inflammation, emerged as a leading biomarker. This review synthesises the pivotal literature published between 2000 and 2010 that established the relationship between elevated hs-CRP and the risk of atherosclerotic cardiovascular disease.

Literature Review: A substantial body of evidence from large-scale prospective studies and meta-analyses during this period consistently demonstrated that hs-CRP was a powerful and independent predictor of future cardiovascular events, including myocardial infarction and stroke. Its predictive value was shown to be additive to that of traditional risk factors, including lipid levels. The pathophysiological basis was clarified, with research confirming that inflammation mediates every stage of atherogenesis, from lesion initiation to plaque rupture. Consequently, clinical practice guidelines were issued recommending the use of hs-CRP for enhanced risk stratification in select patient groups. This "inflammation hypothesis" was ultimately validated in a landmark clinical trial, JUPITER, which showed that targeting individuals with elevated hs-CRP with statin therapy significantly reduced major cardiovascular events, even in those with normal cholesterol levels.

Conclusion: The evidence from 2000-2010 conclusively established hs-CRP as a valuable biomarker for cardiovascular risk assessment and solidified inflammation as a central, modifiable component in the pathogenesis of atherosclerosis.